New dosing schedules of dasatinib for CML and adverse event management.

Authors:
Wong SF.

Journal:
J Hematol Oncol

Publication Year: 2009

DOI:
10.1186/1756-8722-2-10

PMCID:
PMC2649947

PMID:
19236716

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Hematol Oncol

Abbreviation: J Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y and 11 more (2024) - Transparency Score: 3/6
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future impl…
Zhao B; Wu B; Feng N and 4 more (2023) - Transparency Score: 3/6
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promisin…
Yang L; Chu Z; Liu M and 7 more (2023) - Transparency Score: 3/6
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and …
Short NJ; Muftuoglu M; Ong F and 24 more (2023) - Transparency Score: 4/6
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic ef…
Li Y; Liu J; Chen W and 13 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests SFW has received honoraria for serving as a consultant at advisory boards for BMS."

Evidence found in paper:

"AcknowledgementsProfessional writing and editorial support provided by Dr. Laura Shepherd, Dr. Johnathan C. Maher, and Mr. Josh Collis, funded by Bristol-Myers Squibb."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025